Glucocorticoid Sparing of Benralizumab in Asthma
- 21 September 2017
- journal article
- letter
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 377 (12), 1204-1205
- https://doi.org/10.1056/nejmc1709523
Abstract
Nair et al. (June 22 issue)1 found in the ZONDA trial that the median blood eosinophil counts fell dramatically after treatment with benralizumab. In a previous trial, Bleecker et al.2 found that blood eosinophil counts were reduced by benralizumab treatment. To avoid bias, what was done to prevent unmasking of the trial-group assignment to the investigators by means of the patients’ eosinophil counts?Keywords
This publication has 5 references indexed in Scilit:
- Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe AsthmaThe New England Journal of Medicine, 2017
- A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitisEuropean Respiratory Journal, 2017
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trialThe Lancet, 2016
- Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a studyThe Lancet Respiratory Medicine, 2014
- Cigarette Smoking Impairs the Therapeutic Response to Oral Corticosteroids in Chronic AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2003